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Rational drug design is a powerful method in which new and innovative therapeutics can 
be designed based on knowledge of the biological target aiming to provide more 
efficacious and responsible therapeutics. Understanding aspects of the targeted biological 
agent is important to optimize drug design and preemptively design to slow or avoid drug 
resistance. Chagas disease, an endemic disease for South and Central America and 
Mexico is caused by Trypanosoma cruzi, a protozoan parasite known to consist of six 
separate genetic clusters or DTUs (discrete typing units). Chagas disease therapeutics are 
problematic and a call for new therapeutics is widespread. Many researchers are working 
to use rational drug design for developing Chagas drugs and one potential target that 
receives a lot of attention is the T. cruzi trans-sialidase protein. Trans-sialidase is a 
nuclear gene that has been shown to be associated with virulence. In T. cruzi, trans-
sialidase (TcTS) codes for a protein that catalyzes the transfer of sialic acid from a 
mammalian host coating the parasitic surface membrane to avoid immuno-detection. 
Variance in disease pathology depends somewhat on T. cruzi DTU, as well, there is 
considerable genetic variation within DTUs. However, the role of TcTS in pathology 
variance among and within DTU’s is not well understood despite numerous studies of 
TcTS. These previous studies include determining the crystalline structure of TcTS as 
well as the TS protein structure in other trypanosomes where the enzyme is often 
inactive. However, no study has examined the role of natural selection in genetic 
variation in TcTS. In order to understand the role of natural selection in TcTS DNA 
sequence and protein variation, we sequenced 540 bp of the TcTS gene from 48 insect 
vectors. Because all 48 sequences had multiple polymorphic bases, we examined cloned 
sequences from two of the insect vectors. The data are analyzed to understand the role of 
natural selection in shaping genetic variation in TcTS and interpreted in light of the 
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Chapter 1:  Introduction to Chagas 
A Brief History of Chagas Disease and Control Efforts  
 Chagas disease was first described in 1909 by its namesake Dr. Carlos Chagas, 
and his description remains one of the most complete initial descriptions of any tropical 
disease [1]. Carlos Chagas was able to identify the infecting parasite, the vector mode of 
transmission, possible mammalian host species, and clinical symptoms.  Despite the 
initial complete description, over a 100 years later Chagas disease remains one of the 
most impactful neglected diseases in Latin America [1]. As well, the burden of Chagas 
continues to grow and with the modern mobility of humans, Chagas exists globally, with 
an estimated 8 to 10 million people infected worldwide [2]. 
  The protozoan family Trypanosoma contains pathogenic and non-pathogenic 
species [3] including Trypanosoma cruzi, the causative agent of Chagas Disease, and 
Trypanosoma brucei, the etiological agent of African Sleeping Sickness. The main 
transmission mode for Chagas is through insect vectors of the subfamily Triatominae [4]. 
The T. cruzi life cycle is often split into two phases: the insect vector cycle and the 
mammalian host cycle. The vector cycle includes the parasite being introduced to the 
vector through a blood meal of an infected mammal host, where the parasite is taken up 
as trypomastigotes  [5]. Once inside the insect, the parasite progresses to the midgut as an 
epimastigote, where it proliferates, eventually progressing to the hindgut as metacyclic 
trypomastigote [5]. When the triatomine takes a subsequent blood meal, the parasite 
passes from the hindgut and is deposited in the feces onto the skin of the mammal blood 
source. This marks the transition from the insect vector and to the pathogenic human 
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cycle where the metacyclic trypomastigotes may enter the bite-wound site or through a 
mucous membrane into the host bloodstream. Once a mammal is infected the 
trypomastigotes enter cells, and transform into amastigotes which continue to proliferate 
within cells of infected tissues [5].  
 Understanding the parasite life-cycle allows for two distinct paths for managing 
the impact and reach of Chagas disease, one being through vector control. The second 
path, the topic of this thesis, is exploring possible pharmacological advancements 
specifically targeting the parasite within mammalian hosts through new drugs. 
Vector control has been a primary method for reducing Chagas disease in many 
of the endemic countries in South and Central America and Mexico and has been 
especially effective in the South American countries where large multidisciplinary efforts 
were made. One large effort to reduce Chagas transmissions was the Southern Cone 
Initiative which was a coordinated effort between six South American countries 
(Argentina, Bolivia, Brazil, Chile, Paraguay, and Uruguay) by the World Health 
Organization (WHO) [6]. One of the main goals of the Southern Cone Initiative was to 
eradicate the main insect vector for the region, Triatoma infestans, largely through 
insecticide spraying of infested and at-risk dwellings [7]. The initiative was considered 
successful in most of the Southern Cone countries, drastically reducing populations of T. 
infestans and thus effectively reducing vector borne transmission and the associated 
economic and societal burdens of Chagas in these countries [8].  
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 However, while successful, the Southern Cone Initiative does have several 
issues that provide reservations to its long term effect and future direction. One of the 
largest issues that needs to be addressed is possible long term effects on human or 
environmental health from the widespread insecticide use. Over 2 million houses were 
sprayed with insecticides ranging from chlorinated hydrocarbons to pyrethoids. 
Additionally in some regions insecticide laden paints were used outside and inside houses 
[7]. The most commonly used insecticide was lindane, a chlorinated hydrocarbon, the 
safety of which in agriculture and pharmacology has been widely debated. This has 
resulted in the chemical being banned, except for occasional pharmacological 
applications (e.g., third line treatment for lice), in over 50 countries including the United 
States [9]. Disregarding the possible benefits for reducing vector transmission of Chagas 
disease, the human toxicity and environmental pollution associated with lindane and 
other insecticides should be considered when evaluating their costs and benefit, in 
Chagas vector control. 
 Other potential challenges of the Southern Cone Initiative include the 
reemergence of T. infestans populations. In regions where T. infestans was originally 
endemic without recurrent insecticide spraying the vector is able to repopulate areas 
where it was previously removed [10]. This not only undermines the goal of the initiative, 
but it also may be a mechanism for the insects to develop insecticide resistance requiring 
the use of higher doses or different insecticides, potentially adding to human and 
environmental health impacts.  
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Vector control is often recognized as interrupting vector borne transmission 
rather than disease eradication or permanent reduction because of the potential for vector 
reemergence or ecological succession (i.e., other vector species replacing a previously 
common vector species) [8]. Vector control through insecticide use is challenging as a 
large-scale solution for the reasons mentioned above and because there simply is not one 
vector for Chagas transmission. There are over 140 species, all within the subfamily 
Triatominae. Epidemiologically important vector species are largely regional and vector 
control is complicated by many factors such as population density and the landscape of a 
region as both contribute to the diversity of vector species in an area.  
The last pitfall of the Southern Cone Initiative to be addressed here is that 
although it reduced the rate and number of new infections, it did not address the 
population of already infected Chagas patients.  Pharmacological advances would address 
both these issues and could be more stable long-term tools in fighting Chagas disease. 
New therapeutics aimed at Chagas need to be developed to improve the ability of 
clinicians to actually treat and possibly one-day cure patients of the disease. Research to 
develop Chagas drugs should be seen as complimenting the progress of vector control 
efforts and provide long term solutions to the existing Chagas patient population and 
offer better outlooks to new Chagas patients. The current pharmacological options 
available to treat Chagas revolve around two drugs Beznidadazole and Nifurtimox both 




Human Pathology of Chagas Disease 
Although Chagas disease in humans occurs mainly through vector transmission, 
congenital infection is also possible as well as infecting through blood and organ 
donations [4]. Human Chagas disease has two main phases: acute and chronic. The short 
acute phase, which lasts from a few weeks to months is largely asymptomatic for many 
patients. For symptomatic cases, acute Chagas can present many symptoms including 
fever, edema, swollen lymph nodes (adenopathy) and localized swelling around the 
parasite entry point, also known as a Chagoma or Romaña’s sign. In terms of acute 
Chagas Chagomas is considered the telltale symptom of T. cruzi infection [12]. The 
severity of the acute phase is contingent on many other factors including mode of parasite 
acquisition, patient age, patient overall health and the infecting DTU. The predominance 
of asymptomatic cases of Chagas presents a dilemma as while it is good that the patient is 
not dealing with potential ill health or life-impacting symptoms, it may mask the presence 
of the disease overall. This is problematic as the acute phase is the most efficacious time 
for the current Chagas drugs, Nifurtimox and Benznidazole [13].  
 Once the disease progresses past the acute phase the parasite enters a largely 
asymptomatic indeterminate phase which last 10-30 years after the initial infection. At 
least 30% of patients have the reemergence of symptoms in the chronic phase [12]. 
Progression of chronic disease within humans is somewhat associated with the particular 
genetic strain of the infecting parasite, but in many aspects is poorly understood [14]. 
Chagas disease that reaches the chronic phase mainly affects tissues of three organs; 
cardiac, esophageal, and intestinal. For example, the strain recognized as TcI often 
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progresses to Chagasic cardiomyopathy. While other strains have also been shown to 
cause Chagasic cardiomyopathy these strains have also been linked to megaesophagus 
and megacolon [14]. In this way diagnosing the infecting DTU becomes important to 
predict the prognosis and further development of the disease, and thus may be useful as a 
diagnostic tool.  
 While there is diversity in symptoms, severity, and progression of the disease, 
the therapeutic tools available lack diversity. Chagas disease as mentioned previously is 
treated predominantly with two drug options Nifurtimox and Benznidazole, both of 
which have toxic effects on the patient [15]. For example Benznidazole causes 
neutropenia and Nifurtimox can cause anorexia [16]. Overall, Benznidazole has less 
common but more debilitating side effects such as dermal hypersensitivity and 
polyneuropathy [11]. Another issue with the availability of only these two drugs is the 
possibility of T. cruzi evolving single drug resistance, and the more challenging 
possibility of cross-resistance between the drugs.  One of the proposed contributing 
factors to the evolution of drug resistance is the inability to complete treatment regimens. 
A typical Nifurtimox course is 10mg/kg/day for 60 or 120 days, the long time frame, 
coupled with the side effects of the drug courses have the consequence that drug 
treatments are often abandoned early [16]. Compounding this issue, studies have shown 
cross resistance, the development of resistance to Nifurtimox by T. cruzi includes cross-
resistance to Benznidazole, effectively removing both treatment options for those patients 
[16].  
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This introductory chapter has introduced some of the ecology, pharmacology and 
challenges for reducing Chagas disease. The next chapter explores genetic variation in a 






Figure 1: Surface anchored trans-sialidase (TS) proteins on the parasite outer 
membrane mediate transfer of sialic acid from the host glycoconjugate to parasite 
surface mucins (sialylation) within a mammal host. The sialylated mucin provides 
parasite protection from the host immune system and helps in parasite adhesion to 
host cells.  TS proteins shed into the host bloodsteam can interact with several cell 
types leading to multiple downstream biological effects. Used with permission from 
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Chapter 2: The role of natural selection in shaping genetic variation in a 
promising Chagas Disease drug target: Trypanosoma cruzi trans-sialidase 
 
Introduction 
Trypanosoma cruzi is a human pathogen responsible for Chagas Disease, also 
known as American Trypanosomiasis. The disease is endemic in Mexico, Central and 
South America and is currently affecting an estimated 8-10 million people with another 
70 million people at risk [1]. Primarily transmitted by insect vectors of the Triatominae 
sub-family (Hemiptera: Reduviidae), T. cruzi displays complex genetic diversity with 
resulting complexity in its pathogenic effects within and between mammalian species [2]. 
Various approaches have been used to characterize the diversity in T. cruzi with the 
general consensus of six major subdivisions known as known as Discrete Typing Units 
(DTUs) and named TcI – TcVI. A seventh DTU (TcBat), found within TcI has been 
brought to recent attention, as well as a lineage found only in bats, T. cruzi marinkelli, 
that forms a sister group to TcI-TcVI [3].  
This heterogeneity in T. cruzi has been shown to be significant in human Chagas 
Disease as certain progressions of the disease have been linked to particular DTUs. For 
example, TcI has been linked to the development of Chagasic cardiomyopathies, while 
other DTUs have been shown to progress to more gastrointestinal symptoms such as 
megaesophagus [4]. 
 Efforts to reduce autochronous Chagas transmission through vector control have 
been remarkably effective. However, in regions where sylvatic populations exist, vector 
control requires repeated use of insecticides around and within homes and such repeated 
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use of insecticides can have adverse ecological and human health effects as well as lead 
to insecticide resistance [5]. Further, although vector control methods have interrupted 
transmission significantly, they fail to address the growing patient population already 
infected. This combination of factors means that new therapeutics are needed. 
The T. cruzi trans-sialidase (TcTS) receptor gene has been suggested as a 
biological target for a rationally designed Chagas drug [6-8,11-13,18]. This receptor is 
essential for parasite growth, because it is a receptor it can potentially be inhibited [6], 
and it has been implicated in virulence [7]. The TcTS receptor harvests sialic acid from 
the mammal host, a molecule critical for eukaryotic proliferation and survival that is 
produced by mammalian cells but not produced by T. cruzi. Among the 
Trypanosomatidae, which includes other human pathogens such as Trypanosoma brucei 
the etiological agent of African sleeping sickness, only T. cruzi is known to be unable to 
produce sialic acid and thus expresses high levels of the TcTS receptor in the 
trypomastigote stage (the stage infecting vertebrate blood) [7].  The TcTS receptor 
captures sialic acid from the blood of its mammalian host, transferring it to surface 
mucins coating its outer membrane. The sialidated molecule is important in evading 
immune detection [8]. These features of TcTS make it an excellent target for Chagas 
rational drug development [7].  
 Despite the high potential of the TcTS receptor as a target for drug design, high 
throughput screens for potential TcTS inhibitors have been relatively unsuccessful. One 
possible reason could be genetic diversity of the receptor [7].  
The TcTS genes are part of a large superfamily of over 1400 genes containing the 
conserved VTVxNVxLYNR motif [9]. These genes form eight groups, of which only 
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group 1 codes for active trans-sialidases [10] with estimates of 1-32 enzymatically active 
TcTS gene copies per haploid genome [11]. Of the remaining genes about 700 are 
functional but produce inactive TS, and approximately 700 are pseudogenes [7].  
The TcTS protein has an N-terminal catalytic domain (amino acids 1-371) that 
ends in a six bladed beta propeller, an alpha helix (amino acids 372-394) connects the 
catalytic domain to the C-terminal lectin-like domain (amino acids 395-632). Another 
alpha helix near the C-terminus (amino acids 614-626) is sometimes followed by a 
variable repetitive (100-500 amino acids) hydrophilic, 12 residue shed acute phase 
antigen (SAPA) motif [8].  
Within the N-terminal catalytic domain, group I active TcTS differ from inactive 
forms by a single amino acid replacement, Tyr342His. The transfer of sialic acid from 
host to parasite glycoconjugates catalyzed by TcTS (Figure 2.1a) involves an additional 
seven amino acids known to bind to sialic acid. During the transfer reaction, Tyr342 is 
crucial in forming the covalent intermediate resulting from cleaving the sialic acid from 
the host glycoconjugate (Fig 2.1b) before it is transferred to a parasite glycoconjugate 
(Fig 2.1c) [12].  
Identifying and further exploring the genetic diversity of TcTS is important 
towards drug development since the structure and function of proteins has been shown to 
be sensitive to amino acid changes anywhere in a peptide sequence, not just active 
domains (e.g.,[14]), genetic variation in TcTS may affect susceptibility to inhibitors, and 
may need to be considered when evaluating TcTS for rational drug design.  
 Rational drug design incorporates biological information and aims to create 
more effective and longer lasting therapies. Since drugs act as selective agents, it is 
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important to understand the evolutionary processes acting on a drug target [15]. There are 
several statistical tests to determine if DNA sequence variation results from neutral 
processes, or negative or positive selection [15, 16]. Negative, or purifying selection, is 
the removal of disadvantageous mutations. Positive selection, or adaptive evolution, 
includes the increase in frequency of advantageous mutations as well as types of selection 
important in host-parasite interactions such as balancing selection (also called 
heterozygote advantage or overdominance) and negative frequency-dependent selection 
(i.e., rare alleles are favored). These types of selection have different implications for a 
drug target. It has been suggested that positive selection is not beneficial for a drug target 
while negative selection does add to a targets justification [17].  
 We assessed DNA sequence and protein variability in an ~500 bp region of the 
TcTS gene of T. cruzi isolated from the abdomens of Triatoma dimidiata the major insect 
vector in Central America and Mexico and Triatoma nitida, a species with a more 
restricted geographic range that is sometimes found in sympatry with T. dimidiata.  Our 
T. dimidiata specimens were from Guatemala and El Salvador, and the T. nitida from 
Guatemala. We did Sanger sequencing of 48 PCR products (hereafter referred to as 
PCRp). Because TcTS is a nuclear gene and insects could potentially be infected with 
one or more parasite strains and also because TcTS has 1-32 copies per haploid genome, 
for a subset of the insects we cloned the PCR products prior to sequencing (referred to as 
the 10 cloned sequences).  
The region analyzed starts in the N terminal catalytic domain (amino acids 269 to 
371), extends into the alpha helix (372-394) and ends in the C-terminal lectin-like domain 
(amino acids 373 to 434). This region includes four amino acids important in the binding 
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of sialic acid, Pro238, Trp312, Arg314, and Tyr342 (Table 2). The sequence data were 
used to identify the DTU of T. cruzi infecting the insects and verify we were examining 
sequence from the group I active TcTS subfamily. The sequence data were then analyzed 
for natural selection at both the level of the gene and the level of individual amino acids. 
First, the McDonald Kreitman (MK) test, which considers an entire gene or region of 
DNA, was used to test for selection within homogeneous regions (catalytic vs non-
catalytic) [23,24]. Second, we used Selecton, an amino acid site-specific test [26,27]. The 
MK test was only appropriate for testing the cloned sequences, whereas both the cloned 
and 48 PCRp sequences were examined with Selecton.  
 
Results 
The 58 new TcTS sequences from this study belong to group 1, the only one of 
the eight groups in the superfamily with active TS. Examination of the cloned TcTS 
sequences with the MK test indicated significant balancing selection in the catalytic-
domain of the TcTS gene. The variation was not significantly different from a neutral 
model of evolution for the part of the C-terminal lectin-like domain region examined. In 
addition, for both the cloned and PCRp sequences, the test for selection at each individual 
amino acid site found evidence of positive and negative selection within the regions 
examined. Below we present the data supporting these results. 
Confirmation of TcTS sequences as TS group 1 
Phylogenetic analysis indicated that the sequences are from TcTS group 1 genes 
that code for active TS (Fig. 2.2) with strong statistical support (100% bootstrap support). 
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As expected, all 58 sequences from this study had Tyr342, the critical amino acid that 
distinguishes the active and inactive forms of TS. 
 
Tests for natural selection  
The multi-locus MK test indicated the two regions of the TcTS gene were 
heterogeneous (Table 1b, wMK = 2.077, c2 = 6.205, p < 0.02). We therefore analyzed each 
region separately with the standard MK test.  
We detected statistically significant negative and/or balancing selection in the 
catalytic domain (Table 2, Neutrality index NI = 4.940, c2 = 14.348, p < 0.001). 
Examination of the contingency table (Table 2) shows a higher number of non-
synonymous polymorphisms than synonymous substitutions for this region (Pn = 15 > Ps 
= 8) suggesting balancing selection. 
For the non-catalytic region that included the alpha helix and part of the C-
terminal lectin-like domain, the pattern of variation is consistent with the neutral model 
of evolution (Table 3c, Neutrality index NI = 1.091, c2 = 0.047, p > 0.05).   
The test using Selecton that examined selection at each individual amino acid, 
showed evidence of both positive and negative selection over the region examined (Fig 
2.3). Among the 166 amino acids studied, Selecton identified 59 sites of positive 
selection, including both directional and balancing selection, 81 sites of purifying 
selection and 26 neutral sites. Overall the model including positive selection is a better fit 
to the data than the null model that includes only purifying selection and neutral 
synonymous changes (log likelihood -1227.73, delta-log-likelihood -3.35, p-value < 
0.02). 
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The conservation metric (Fig 2.3) provides an estimate of variation for a 
particular amino acid. Over the region examined, the conservation metric ranges from 0.5 
to 1, with an average value of 0.962. The catalytic domain showed higher average 
conservation (0.982) than the non-catalytic region (0.930).  
Selecton values span the possible range (1 indicates strongest positive, 4 is 
neutral, 7 is strongest purifying). The average selection value over the region examined 
was 4.361, the catalytic region was toward more purifying selection (average of 4.767) 
while the non-catalytic region indicated more positive selection (average of 3.398).  
With respect to the amino acids essential to catalytic activity, sites 283, 342 and 
357 showed negative selection, having both high conservation values and Selecton 
values. Site 314 showed evidence of positive or balancing selection indicated by high 
polymorphism (low conservation) and low Selecton scores, while site 312 was neutral.  
 Comparison of the Selecton values of the 10 clones with the 48 PCRp sequences 
shows the PCRp sequences show fewer sites of positive selection (Fig. 2.4). The selecton 
results of the PCRp sequences identified only 49 positively selected sites, 26 neutral sites, 
and 91 negatively selected sites. The average selecton value for the entire region 
examined was 4.6506, as well using the same division in the sequence as above, the 
catalytic region was more indicating of purifying selection (average of 4.9417) than the 
non-catalytic region (average of 4.1746). Similarly, the average conservation score for 
the entire region analyzed was 0.9564. While the catalytic domain region again showed 





In this study analyzing how natural selection and genetic variation in the TcTS 
gene might affect its potential for rational drug design for our cloned sequences we found 
no DNA or amino acid variation at most of the sites essential to catalytic activity, 
however for one site there was significant diversifying or balancing selection. These 
results are explained in detail below.  
In analyzing selection on our sequences, we first confirmed through phylogenetic 
analysis that our PCRp and cloned sequences represent TcTS protein group 1. This is 
important since TcTS group 1 is the only group within the trans-sialidase protein 
superfamily that produces active trans-sialidase.  
 The MK test, which was appropriate only for the cloned sequences, detected 
heterogeneity in selection between the catalytic domain, which showed signs of balancing 
and negative or purifying selection, and the non-catalytic portion of the protein which 
was not significantly different from expectations of a neutral model of evolution.  
Although the MK test detected an overall signal of balancing or negative selection 
across the catalytic domain, detailed analysis of individual amino acids with Selecton 
confirmed the “negative” selection detected by the MK test to be a combination of 
negative and balancing selection. For the non-catalytic region of the protein, the MK test 
could not reject a neutral model of evolution.  
With respect to the amino acids essential to catalytic activity, three of the five 
sites showed signs of negative selection, consistent with the explanation of low variation 
because most mutations are deleterious and recessive and are removed by selection or 
linger in the population at low frequency (e.g., sites 283, 342 and 357). However, 
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although most amino acids critical to protein function are under negative selection, one 
site 314 indicated balancing selection while site 312 has a neutral selecton value.  
Analysis with Selecton shows quite a few amino acids under positive (balancing) 
selection in the C-terminal domain, 24 showed positive selection, 12 sites neutral and 27 
sites showed negative selection.   
For the case of the variation at Arg314, there is variation within the clonal 
sequences for one sample. However, the all other clonal samples and the 48 PCRp 
sequences are conserved for this site with no DNA variation.  
Viewing the Selecton values on the 3D structure can help to identify how 
selection is distributed structurally. Projection of the selecton scores on the 3D structure 
of the protein (Fig. 2.4) reveals that the region of the catalytic domain sequenced in this 
study contains 60 of the overall 81 negatively selected sites indicating that there is strong 
constraint on the TcTS structure.  
A multiple sequence alignment (MSA) was constructed with the PCRp and clone 
sequences combined with Genbank reference samples spanning all eight TS gene and 
pseudogene groups. The MSA facilitates examination of the amino acids essential to 
catalytic activity in the region sequenced in this study (S1). Among the 58 PCRp and 
Clone samples there is no DNA variation for three of the amino acids essential to TS 
transfer activity. In contrast, TS groups 2-8 show some significant variation at these sites. 
The amino acid variation at these sites was not conserved with any discernable pattern, 
that is TS groups 2 - 8 did not have distinct variation based on the respective TS group, 
and no pattern was discernable based on the taxa of the sequences.  
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How do these results inform rational drug design? Regions of purifying selection 
are considered strong targets. We detect strong negative selection for the amino acid that 
distinguishes active and inactive TcTS, Tyr342.  
In contrast, regions of positive selection indicating adaptive evolution are not 
desirable drug targets. This is because positively selected regions show variability and the 
potential of the parasite to develop drug resistance. Drug targets should avoid positively 
selected amino acids such as Arg314, an amino acid important in the carboxylation step 
of TcTS activity.   
 Drug design should work to develop inhibitors acting specifically at sites such as 
Tyr342 that are crucial to the protein function and under negative (purifying) selection. 
Specificity ensures an inhibitor is acting on the desired amino acid residue and can be 
measured experimentally. A promising inhibitor believed to be specific for Tyr342 could 
tested by mutating or removing Tyr342 (e.g., through site-directed mutagenesis) and 
determining if the inhibitor exhibits lower affinity. For example, a recent study using 
drug repositioning to identify possible trypanocidal agents acting on TcTS [18] could also 
test the specificity of promising compounds with respect to identified critical and 
negatively selected amino acids. Trypanocidal agents specific to sites under negative 
selection would be preferential for long term drug efficacy than ones specific to sites 
under positive selection. Drug development for Chagas disease may consider not only 
anti-parasitic drugs but also anti-virulent drugs. 
In summary, this study analyzing natural selection and genetic variation in the 
TcTS gene identified regions of purifying, balancing and positive selection in the TcTS 
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protein. Rational drug design should consider this variation to increase the likelihood of 
developing effective drugs with lower chances for the evolution of drug resistance.  
 
Methods 
Insect vectors, DNA isolation, PCR and sequencing 
 We examined parasites from two species of insect vectors, Triatoma dimidiata 
and Triatoma nitida (Table 1). The T. dimidiata were collected from three departments 
(Huehuetenango, Quiche and Jutiapa) in Guatemala and four in El Salvador (Morazan, 
Santa Ana, Ahuachapan, Sonsonate). The T. nitida were from two departments in 
Guatemala (Huehuetenango and Chiquimula). 
The T. cruzi DNA was extracted from the last two segments of each insect 
abdomen using previously described methods [19]. The PCR amplification used primers 
(TS 31: TCACGCAGCGGTACGCATCCT, TS 51: GGAGGCTGTCGGCACGCTCTC) 
specific to group I TS genes that make active trans-sialidases [11].  The PCR conditions 
were as previously reported [11] and PCR results were confirmed via gel electrophoresis. 
Samples showing the appropriate size PCR product were sequenced by a commercial 
facility (Genewiz, South Plainfield, NJ). 
The PCR reaction amplified 540 bp and we analyzed a fragment coding for 166 
amino acids of the TcTS protein. The region analyzed includes five amino acid residues 
identified as important to the function and structure of the protein (Table 2): Pro238, 
Trp312, Arg314,  Tyr342 and Glu357 [8] including the critical amino acid Tyr342His 
that distinguishes the active and inactive forms, but not including the conserved 
VTVxNVxLYNR motif [9].  
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 The sequence files were trimmed to 498 bp removing the primer regions and 
edited using Sequencher (V5). Heterozygous peaks were evidence of polymorphism 
within an insect vector. Two insect vectors were selected for cloning to resolve the 
heterozygous peaks and identify haplotypes. We cloned fresh TcTS PCR product using 
the pGEM-T Easy cloning kit (Promega) following the manufacturer’s instructions for 
both ligation and transformation, specifically using the pGEM-T Easy Vector, T4 DNA 
Ligase, and JM109 High Efficiency Competent Cells (Promega). In order to confirm the 
success of the transformation both ampicillin selection and a blue-white screen were 
used. Harvested white colonies were boiled to lyse the cells and extract DNA which was 
then PCR- amplified and sequenced as described above. The cloned sequences are 
hereafter referred to as such. The non-cloned, PCR product sequences are referred to as 
PCRp hereafter.  
 
Confirmation of TcTS sequences as TS group 1 
Our cloned and PCRp sequences were combined with GenBank TcTS sequences 
and other Trypanosoma species trans-sialidase sequences (Table 1) for a total of 102 
sequences; 58 new from this study and 34 from Genbank. The 58 sequences from this 
study include 48 PCRp sequences and 10 cloned sequences (four from one and six from a 
second of the 48 PCRp sequences).  
 
Phylogenetic analysis was used to confirm the TcTS group of the 58 sequences 
new from this study by comparison with reference sequences [9]. The sequences were 
aligned with ClustalW in MEGA (V7) and translated into amino acid sequences based on 
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GenBank reference sequences. Alignment and translation was performed with T-Coffee 
[20-22]. 
The sequences were analyzed in ProtTest (V2.4) to identify the best model 
parameters for construction of the phylogenetic tree.  RaxML(V8.0.0) was used to 
construct the phylogeny within the CIPRES Science Gateway V3.3 server combined with 
bootstrapping to quantify branch support. The optimal tree output was then drawn in 
FigTree (V1.4.3). 
 
Tests for natural selection  
Two tests were done to determine the role of natural selection in TcTS DNA 
sequence variation and evolution, specifically, the McDonald-Kretiman (MK) test [23,24] 
which considers an entire gene (or portion) and Selecton, an amino acid site-specific test 
[26,27]. The 10 cloned sequences were examined with both the MK test and Selecton. 
Because of the ambiguous nucleotide sites, the 48 PCRp sequences could only be 
examined with Selecton. 
To examine the role of neutral vs selective processes for the cloned sequences we 
used an online version for the MK test [23, 24]. Trypanosoma brucei group 1 TS 
(AF310232) was used as the outgroup [9]. The MK test assumes homogeneity across the 
gene, but because different regions of the TS gene may evolve differently, we used the 
multi-locus MK test to test for heterogeneity of part of the region with the N terminal 
catalytic domain (amino acids 269 to 371) compared to the region with the alpha helix 
(372-394) and part of the C-terminal lectin-like domain region (amino acids 373 to 434). 
Then we used the standard MK test to test for selection within homogeneous regions.  
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The MK test compares the within (polymorphic) T. cruzi non-synonymous to 
synonymous (neutral) changes (Pn/Ps [19]) to the between species (divergent) T. cruzi - 
T. brucei non-synonymous to synonymous changes (Dn/Ds) using a Chi-square test. The 
Neutrality Index (NI) indicates the strength of departure from the neutral model [25]: 1 
indicates the data are consistent with a neutral model of evolution, > 1 indicates either Dn 
is lower than expected due to purifying selection against harmful mutations or Pn is 
higher than expected due to balancing selection, and < 1 indicates Dn is high due to an 
excess of fixation of non-neutral replacements from adaptive evolution or Ps is low [25].  
In addition, selection at each individual amino acid site was examined and 
correlated with the protein structure using the Selecton 2007 online server 
(http://selecton.tau.ac.il/)[26, 27] . The test used Bayesian inference to calculate the 
dN/dS ratio and used a likelihood ratio test to compare a model with positive selection 
(their M8) with a null model (M8a) that assumes only purifying selection and neutral 
changes. The selection values for each amino acid ranged from 1 ( strong negative 
selection) to 7 (strong positive selection) and were projected on the 3D structure of the 
protein using the tool First Glance in Jmol (FGiJ, http://firstglance.jmol.org, PDB 1S0I) 
implemented in Selecton [26, 27]. 
In interpreting the results, for the MK test, NI < 1 (“positive” selection) refers to 
adaptive evolution through directional selection; whereas NI > 1 (“negative” selection) 
includes both purifying and balancing selection. For the Selecton test, negative selection 
refers to purifying selection, while positive selection refers to adaptive evolution through 
directional and balancing selection.   
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Finally, to compare the variation among the cloned sequences with the variation 
among the PCRp sequences, we calculated the conservation for each amino acid, on a 
scale of 0 to 1, where no variation = 1. Using the most common amino acid at each site as 
the reference, each amino acid was assigned a value of 1 if was identical to the reference, 
0.5 if the variation did not change the amino acid class (e.g., polar to polar or negative 
charge to negative charge), and 0 if the variation caused a substitution of a different 
amino acid class (e.g., polar to negative charge). The sum for each site was divided by the 
number of total sequences (10 for clones and 48 for PCRp) creating a conservation score 
between 0 and 1 for each site. 
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Table 1: Comprehensive list of newly sequenced samples and Genbank reference samples 
used in this study. 
 
 
Species Sample or Isolate ID Vector Species TS Protein Group Country collected Department Latitude (N) Longitude (W) Accession Number
Trypanosoma cruzi A10050-TS Triatoma dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 21´30.815¨ 91° 27´5.12¨
T. cruzi A10051-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 21´30.815¨ 91° 27´5.12¨
T. cruzi A10052-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 21´30.815¨ 91° 27´5.12¨
T. cruzi A10053-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 21´30.815¨ 91° 27´5.12¨
T. cruzi A10054-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10055-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10062-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15°24′00″ 91°58′00″
T. cruzi A10063-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15°24′00″ 91°58′00″
T. cruzi A10067-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 40´46.271¨ 91° 49´7.159¨
T. cruzi A10071-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 21´30.815¨ 91° 27´5.12¨
T. cruzi A10083-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10227-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10230-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 39´ 5.85¨ 91° 46´16.903¨
T. cruzi A10231-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 39´ 5.85¨ 91° 46´16.903¨
T. cruzi A10232-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 39´ 5.85¨ 91° 46´16.903¨
T. cruzi A10250-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15°20′35″ 91°18′42″
T. cruzi A10304-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10305-TS Triatoma nitida TS group 1 ( T. cruzi clade) Guatemala Huehuetenango 15° 19´10.709¨ 91° 29´ 32.358¨
T. cruzi A10308-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10311-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A10313-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Huehuetenango
T. cruzi A8974-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Quiche 14° 55´23.401¨ 90° 39´45.567¨
T. cruzi A9948-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Jutiapa 14° 16´44.899¨ 89° 52´31.972¨ 
T. cruzi A9950-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Jutiapa 14° 16´44.899¨ 89° 52´31.972¨ 
T. cruzi FER530-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Morazan 13	55'	46"	N 88	11'	12"	W
T. cruzi FER535-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Morazan 14°04'49.0"			 89°32'09.9"		
T. cruzi S234-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14°03'54.6"			 89°31'46.3"		
T. cruzi S236-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14°03'54.6"			 89°31'46.3"		
T. cruzi S238-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14°03'54.6"			 89°31'46.3"		
T. cruzi S328-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Ahuachapan 13° 58' 0" 89° 49' 0"
T. cruzi S354-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Sonsonate 13° 42' 0"  89° 37' 0"
T. cruzi S384-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Ahuachapan 13° 58' 0" 89° 49' 0"
T. cruzi S445-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Sonsonate 13° 45' 43" 89° 31' 36"
T. cruzi S448-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Sonsonate 13° 45' 43" 89° 31' 36"
T. cruzi S455-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador Sonsonate 13° 45' 43" 89° 31' 36"
T. cruzi S478-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 13° 52´ 59¨ 89° 28´ 59¨
T. cruzi S486-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 13° 52´ 59¨ 89° 28´ 59¨
T. cruzi S507b-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 13° 52´ 59¨ 89° 28´ 59¨
T. cruzi TPG1019-TS T. nitida TS group 1 ( T. cruzi clade) Guatemala Chiquimula 14° 41´36¨ 89° 22´23.4¨
T. cruzi TPG891-TS T. nitida TS group 1 ( T. cruzi clade) Guatemala Chiquimula 14° 41´36¨ 89° 22´23.4¨
T. cruzi TPG892-TS T. nitida TS group 1 ( T. cruzi clade) Guatemala Chiquimula 14° 41´36¨ 89° 22´23.4¨
T. cruzi TPG1239-TS T. nitida TS group 1 ( T. cruzi clade) Guatemala Chiquimula 14° 41´36¨ 89° 22´23.4¨
T. cruzi TPG1247-TS T. nitida TS group 1 ( T. cruzi clade) Guatemala Chiquimula 14° 41´36¨ 89° 22´23.4¨
T. cruzi TPG761-TS T. dimidiata TS group 1 ( T. cruzi clade) Guatemala Chiquimula 14° 43´18.36¨ 89° 16´31.32¨
T. cruzi TPS053-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14°03'54.6"			 89°31'46.3"		
T. cruzi TPS180-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14° 6' 0" 89° 27' 0"
T. cruzi TPS400-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14° 6' 0" 89° 27' 0"
T. cruzi TPS68-TS T. dimidiata TS group 1 ( T. cruzi clade) ElSalvador SantaAna 14°4'45" 89°31'54"
Control  Samples
T. cruzi TcCM187-TS TS group 1 ( T. cruzi clade)
T. cruzi TcI-TS TS group 1 ( T. cruzi clade)
T. cruzi TcV-TS TS group 1 ( T. cruzi clade)
T. cruzi TcVI-TS TS group 1 ( T. cruzi clade)
Clonal Samples
T. cruzi A9950_RE1 TS group 1 ( T. cruzi clade)
T. cruzi A9950_RE2 TS group 1 ( T. cruzi clade)
T. cruzi A9950_RE3 TS group 1 ( T. cruzi clade)
T. cruzi A9950_RE7 TS group 1 ( T. cruzi clade)
T. cruzi A9950_RE8 TS group 1 ( T. cruzi clade)
T. cruzi A9950_RE12 TS group 1 ( T. cruzi clade)
T. cruzi A10055_RE2 TS group 1 ( T. cruzi clade)
T. cruzi A10055_RE4 TS group 1 ( T. cruzi clade)
T. cruzi A10055_RE5 TS group 1 ( T. cruzi clade)
T. cruzi A10055_RE7 TS group 1 ( T. cruzi clade)
Genbank Samples Accession	number
T.	cruzi G/TCC30 Opossum TS	group	2 Brazil EF154827
T.	cruzi G/TCC31 Opossum TS	group	2 Brazil AF426132
T.	cruzi CA-I H.	sapiens TS	group	1 Argentina X57235
T.	cruzi CL Triatoma	infestans TS	group	7 Brazil X70948
T.	cruzi CL T.	infestans TS	group	2 Brazil AF128843
T.	cruzi CL	Brener T.	infestans TS	group	2 Brazil XM_799078
T.	cruzi CL	Brener T.	infestans TS	group	5 Brazil XM_800086
T.	cruzi CL	Brener T.	infestans TS	group	2 Brazil XM_800788
T.	cruzi CL	Brener T.	infestans TS	group	1 Brazil XM_802406
T.	cruzi CL	Brener T.	infestans TS	group	3 Brazil XM_802711
T.	cruzi CL	Brener T.	infestans TS	group	4 Brazil XM_803072
T.	cruzi CL	Brener T.	infestans TS	group	6 Brazil XM_803086
T.	cruzi CL	Brener T.	infestans TS	group	5 Brazil XM_803518
T.	cruzi CL	Brener T.	infestans TS	group	2 Brazil XM_805296
T.	cruzi CL	Brener T.	infestans TS	group	7 Brazil XM_805583
T.	cruzi CL	Brener T.	infestans TS	group	4 Brazil XM_806976
T.	cruzi CL	Brener T.	infestans TS	group	8 Brazil XM_807627
T.	cruzi CL	Brener T.	infestans TS	group	1 Brazil XM_808522
T.	cruzi CL	Brener T.	infestans TS	group	8 Brazil XM_808523
T.	cruzi CL	Brener T.	infestans TS	group	6 Brazil XM_809532
T.	cruzi CL	Brener T.	infestans TS	group	4 Brazil XM_810613
T.	cruzi CL	Brener T.	infestans TS	group	2 Brazil XM_812072
T.	cruzi CL	Brener T.	infestans TS	group	2 Brazil XM_811278
T.	cruzi CL	Brener T.	infestans TS	group	2 Brazil XM_811657
T.	cruzi CL	Brener T.	infestans TS	group	3 Brazil XM_814626
T.	rangeli DOG82 Dog TS	group	2 Venezuela FJ404802
T.	rangeli DOG83 Dog TS	group	2 Venezuela FJ404803
T.	rangeli DOG84 Dog TS	group	2 Venezuela AF426022
T.	rangeli Choachi R.	prolixus TS	group	8 Colombia KC544946
T.	rangeli Choachi R.	prolixus TS	group	5 Colombia KC544956
T.	Brucei TREU927 Glossina	sp TS	group	1 Kenya XM_842470
T.	Brucei EATRO	427 Sheep TS	group	1 Uganda AF310232
T.	carassii cyprinid	fish TS	group	1 AY142111




Table 2: Genetic variation and selection for the TcTS amino acids essential to catalytic 




















Residue	 Possible	Role	 Clone	Variation Clone	Selection PCRp	Variation PCRp	Selection
Pro	283 Transglycosylation/Hydroxylation	 None Purifying None Purifying
Trp	312 Aromatic	Sandwich/Hydrogen	Bonding None Positive None Purifying
Arg	314 Carboxylate	Fixation Non-synonymous Neutral None Purifying
Tyr	342 Enzymatic	Nucleophile None Purifying None Purifying
Glu	357 Catalysis	 None Purifying None Purifying
 30 
Table 3: Results of multi-locus McDonald Kreitman test for the N-terminal catalytic 













Polymorphism Divergence Total Neutrality	Index c2  p-value
Region	1 Neutral 8 209.8 217.8
Non-neutral 15 79.62 94.62
Total	 23 289.42 312.42
Polymorphism Divergence Total Neutrality	Index c2  p-value
Region	2 Neutral 13 32.76 45.76
Non-neutral 26 60.04 86.04 1.091 0.047 0.828












Fig 2.1 Chemical reaction catalyzed by Trypanosoma cruzi trans sialidase (TcTS)..  
Mechanism of removal of sialic acid from host, creating a stable covalent intermediate. 


















Fig 2.2 Best Maximum Likelihood tree reconstruction for the trans-sialidase (TS) protein 
family constructed from T. cruzi TS samples and GenBank reference samples for each 



















































































































Fig 2.3 Summary of results, showing DNA and amino acid sequence variation, and 
results of the analysis of Selecton test for natural selection. Based on analysis of the 10 
clone sequences. Rows (identified with ALL CAPITAL LETTERS) indicate: 
SELECTON, the Selecton score (Orange is strong positive selection, light pink is neutral 
and purple is strong negative selection); POSITION, the amino acid position in the TcTS 
protein (our sequences cover amino acids 269-434); AA, the amino acid for each of the 
10 clones; and DNA, the corresponding nucleotides for each amino acid. The blue line 
shows the Selecton score for each amino acid with the red horizontal line indicating 
neutral evolution or no selection. The blue histograms show the conservation of each 






Fig. 2.4 Comparison of Selection values between the clone and 48 PCRp sequences. 
Orange indicates strong positive selection, yellow is neutral and magenta is strong 
negative selection.The catalytic region is outlined in green and the non-catalytic region is 



















Fig. 2.5 Three-dimension projection of Trypanosoma cruzi trans-sialidase (TcTS) 
molecule with amino acids shaded to indicate Selection values. A. N-terminal catalytic 
domain. B. alpha-helix domain, C. C-terminal lectin-like domain. D. Highlight of 
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